Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)

Acute megakaryoblastic leukemia (M7 AML) is a highly aggressive disease. We evaluated outcomes in 57 children (11 with Down syndrome) and 69 adults with M7 AML after first complete remission (CR1) following autologous or HLA-identical allogeneic transplantation. Characteristics of the recipients of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2005-01, Vol.105 (1), p.405-409
Hauptverfasser:	Garderet, Laurent, Labopin, Myriam, Gorin, Norbert-Claude, Polge, Emmanuelle, Baruchel, André, Meloni, Giovanna, Ortega, Juan, Vossen, Jaak, Bunjes, Donald, Leverger, Guy, Blaise, Didier, Ferrant, Augustin, Brune, Mats, Dore, Eric, Gadner, Helmut, Zintl, Felix, Yaniv, Isaac, Dini, Giorgio, Frassoni, Francesco
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Bone marrow, stem cells transplantation. Graft versus host reaction Child Child, Preschool Disease-Free Survival Down Syndrome - complications Europe Female Graft vs Host Disease - immunology Hematologic and hematopoietic diseases Hematopoietic Stem Cell Transplantation - adverse effects Humans Infant Leukemia, Megakaryoblastic, Acute - complications Leukemia, Megakaryoblastic, Acute - immunology Leukemia, Megakaryoblastic, Acute - pathology Leukemia, Megakaryoblastic, Acute - surgery Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Middle Aged Prognosis Recurrence Retrospective Studies Survival Rate Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation, Autologous - adverse effects Transplantation, Homologous - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!